Japanese Pharma Looking Beyond Japan For Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease
You may also be interested in...
Forget China And India, Clinical Trial Opportunities In Malaysia and South Korea
The opportunities for clinical trials in China and India are well known to the pharmaceutical industry at this point, but Edward Ian, senior director of clinical operations for PRA International-Asia Pacific, wants company leaders to take notice and advantage of the potential in other countries in Asia Pacific
Forget China And India, Clinical Trial Opportunities In Malaysia and South Korea
The opportunities for clinical trials in China and India are well known to the pharmaceutical industry at this point, but Edward Ian, senior director of clinical operations for PRA International-Asia Pacific, wants company leaders to take notice and advantage of the potential in other countries in Asia Pacific
Wyeth Signs Clinical Trial Partnership With Japan's Largest Hospital Network
TOKYO - Wyeth's fully owned Japanese subsidiary signed a clinical trial partnership agreement with National Hospital Organization, the Japanese government body that manages most national hospitals, becoming the first pharmaceutical maker clinching such an accord with the largest hospital network in the country, Wyeth K.K. spokesman Ken Takashima said July 7